1IA
RPRX icon

1834 Investment Advisors’s Royalty Pharma RPRX Stock Holding History

1834 Investment Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,500
Closed -$335K – 211
2025
Q3 		$335K Hold
9,500
– – 0.04% 185
2025
Q2 		$342K Hold
9,500
– – 0.04% 181
2025
Q1 		$296K Hold
9,500
– – 0.04% 187
2024
Q4 		$242K Buy
+9,500
New +$252K 0.03% 201

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1834 Investment Advisors's RPRX Position: Q4 2025 in Review

1834 Investment Advisors sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 9,500 shares — an estimated $335K sold.

1834 Investment Advisors first reported a position in RPRX in Q4 2024 and held it in 4 quarters. The position peaked at $342K in Q2 2025. 540 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • 1834 Investment Advisors reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • 1834 Investment Advisors sold 9,500 Royalty Pharma shares in Q4 2025, an estimated $335K.
  • 1834 Investment Advisors first reported a position in Royalty Pharma in Q4 2024 and held it in 4 quarters.
  • 1834 Investment Advisors's Royalty Pharma position peaked at $342K in Q2 2025.
  • 540 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on 1834 Investment Advisors's 13F filing for Q4 2025, filed 29 Jan 2026.